有创机械通气(invasive mechanical ventilation,IMV)是重症监护病房(intensive care unit,ICU)内呼吸衰竭与呼吸停止患者重要的救治方法。长时间机械通气会引起呼吸性相关肺损伤的发生,而过早拔管脱机也会增加再次插管的概率。因此,脱...有创机械通气(invasive mechanical ventilation,IMV)是重症监护病房(intensive care unit,ICU)内呼吸衰竭与呼吸停止患者重要的救治方法。长时间机械通气会引起呼吸性相关肺损伤的发生,而过早拔管脱机也会增加再次插管的概率。因此,脱机时间对于治疗至关重要,如何准确判断脱机时间成了目前临床上亟待解决的问题。床旁超声是目前临床上判断脱机拔管的重要方法之一,本文对近年来床旁超声预测IMV患者脱机指标进行综述。展开更多
Double-copy retroviral vector containing human factor Ⅸ cDNA driven by human cytomegalovirus enhancer-promoter was constructed. The vector was introduced into the amphotropic packaging cell line PA317. The recombinan...Double-copy retroviral vector containing human factor Ⅸ cDNA driven by human cytomegalovirus enhancer-promoter was constructed. The vector was introduced into the amphotropic packaging cell line PA317. The recombinant virus produced in PA317 was used to transduce skin fibroblasts from a hemophilia B patient. The infected cells produced high levels of biologically active human factor Ⅸ at a rate of 3420 ng/10~6 cells/24 h. These cells were embedded in a collagen matrix and implanted into the peritoneal cavity or subcutaneous space of mice. It was demonstrated that human factor Ⅸ was produced by the implants for at least 12 days in vivo, reaching a peak of 105 ng/ml plasma. Over 90% of the protein was functionally active. This technique has the potential to be developed into a new approach for gene therapy for hemophilia B.展开更多
文摘有创机械通气(invasive mechanical ventilation,IMV)是重症监护病房(intensive care unit,ICU)内呼吸衰竭与呼吸停止患者重要的救治方法。长时间机械通气会引起呼吸性相关肺损伤的发生,而过早拔管脱机也会增加再次插管的概率。因此,脱机时间对于治疗至关重要,如何准确判断脱机时间成了目前临床上亟待解决的问题。床旁超声是目前临床上判断脱机拔管的重要方法之一,本文对近年来床旁超声预测IMV患者脱机指标进行综述。
文摘Double-copy retroviral vector containing human factor Ⅸ cDNA driven by human cytomegalovirus enhancer-promoter was constructed. The vector was introduced into the amphotropic packaging cell line PA317. The recombinant virus produced in PA317 was used to transduce skin fibroblasts from a hemophilia B patient. The infected cells produced high levels of biologically active human factor Ⅸ at a rate of 3420 ng/10~6 cells/24 h. These cells were embedded in a collagen matrix and implanted into the peritoneal cavity or subcutaneous space of mice. It was demonstrated that human factor Ⅸ was produced by the implants for at least 12 days in vivo, reaching a peak of 105 ng/ml plasma. Over 90% of the protein was functionally active. This technique has the potential to be developed into a new approach for gene therapy for hemophilia B.
